SURVYR

AGIO

Agios Pharmaceuticals, Inc.
$38.03
+$1.18 (3.20%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-48%-33%-17%-1%+15%Oct 2025Oct 2026Apr 202652w high $46.0052w low $22.24
AGIOSPY
Wall St. Highest PT $72.00 (+89.3%) Wall St. Avg PT $45.88 (+20.6%)
$22$35$48$61$74POC $28Hi $72Avg $46
Underwater Drawdown %Max DD -50.9%Current -16.4%
0.0%-50.9%
Relative Strength vs SPY-25.3% vs SPYUnderperforming
+57%0%-57%
1W
+$1.39 (3.79%)
1M
+$5.45 (16.73%)
3M
+$2.04 (5.67%)
6M
+$13.23 (53.35%)
YTD
+$10.81 (39.71%)
1Y
−$5.05 (11.72%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
10 analysts · mean score 1.60
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy770%
Hold330%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$38.03
Average target$45.88
+$7.85 (+20.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$32.00
Median$43.50
High$72.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-07 · Truist Securities reiterated Buy on AGIO
Reiterated
2026-09-21 · B of A Securities reiterated Buy on AGIO
Reiterated
2026-08-07 · JP Morgan reiterated Neutral on AGIO
Reiterated
2026-07-31 · Citigroup reiterated Buy on AGIO
Reiterated
2026-07-31 · Truist Securities reiterated Buy on AGIO
Reiterated
2026-07-30 · HC Wainwright & Co. reiterated Buy on AGIO
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.2B
P/E (next 12 months, estimated)-9.1
52-week range$22.24 – $46.00
Revenue growth (latest quarter vs a year ago)+259.3%
Dividend yieldNo dividend
Analyst consensusBuy (8)
Average analyst price target$45.88 (+21%)

What they do

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for AGIO yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

AGIO earningsNext report in 9 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$1.23 range -$1.64–-$1.06
Revenue consensus$51.5M 10 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026-$1.69est -$1.66−1.5%Below estimates
Apr 29, 2026-$1.69est -$1.79+5.7%Above estimates
Feb 12, 2026-$1.85est -$1.94+4.9%Above estimates
Oct 30, 2025-$1.78est -$1.90+6.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-25 12:14:51 ET
24-1025-0225-0525-0725-1026-0226-0426-07-1.947.91
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$44.7M+259.3%
2026-03-31$20.7M–
2025-12-31$20.0M–
2025-09-30$12.9M–
2025-06-30$12.5M–

News & catalysts

More news
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Zacks · Oct 21
Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?
Simply Wall St. · Oct 20
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
CNW Group · Oct 20
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
Stocktwits · Oct 19
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
Zacks · Oct 16
Rating changes
Reiterated
2026-10-07 · Truist Securities reiterated Buy on AGIO
Reiterated
2026-09-21 · B of A Securities reiterated Buy on AGIO
Reiterated
2026-08-07 · JP Morgan reiterated Neutral on AGIO
Reiterated
2026-07-31 · Citigroup reiterated Buy on AGIO
Reiterated
2026-07-31 · Truist Securities reiterated Buy on AGIO
Reiterated
2026-07-30 · HC Wainwright & Co. reiterated Buy on AGIO

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Gheuens Sarah
Chief Medical Officer · 2026-10-22
Sell
$18.8K
Gheuens Sarah
Chief Medical Officer · 2026-10-21
Sell
$55.9K
Gheuens Sarah
Chief Medical Officer · 2026-08-04
Sell
$914.4K

Stats refreshed 2026-10-25 12:14:51 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026